US 2024/0391996 A1Published application

Anti-growth hormone antibody

AssigneeTaisho Pharmaceutical Co., Ltd.

InventorsTomofumi KUROKAWA, Yoshikatsu UEMATSU, Tomoyuki HATA, Hisashi ADACHI, Ayumi SUGITA

Life of this patent

Estimating the term…

Loading patent…

Abstract

In one embodiment, the present invention provides an antibody specifically binding to human GH or an antigen-binding fragment thereof. In one embodiment, the present invention relates to an antibody specifically binding to human GH or an antigen-binding fragment thereof, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises an amino acid sequence set forth in SEQ ID NO: 5 as a VH complementarity-determining region (CDR) 1 (VHCDR1), an amino acid sequence set forth in SEQ ID NO: 6 as a VHCDR2, and an amino acid sequence set forth in SEQ ID NO: 7 as a VHCDR3, and the VL comprises an amino acid sequence set forth in SEQ ID NO: 8 as a VL complementarity-determining region (CDR) 1 (VLCDR1), an amino acid sequence set forth in SEQ ID NO: 9 as a VLCDR2, and an amino acid sequence set forth in SEQ ID NO: 10 as a VLCDR3.

Claims18

Dependent claims

An antibody specifically binding to human growth hormone or an antigen-binding fragment thereof, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein

the VH comprises a VH complementarity-determining region (CDR) 1 (VHCDR1), a VHCDR2, and a VHCDR3,
the VHCDR1 comprises an amino acid sequence set forth in SEQ ID NO:
5, or an amino acid sequence having substitution, addition, or deletion of one or two amino acids in the amino acid sequence set forth in SEQ ID NO:
5,
the VHCDR2 comprises an amino acid sequence set forth in SEQ ID NO:
6, or an amino acid sequence having substitution, addition, or deletion of one or two amino acids in the amino acid sequence set forth in SEQ ID NO:
6,
the VHCDR3 comprises an amino acid sequence set forth in SEQ ID NO:
7, or an amino acid sequence having substitution, addition, or deletion of one or two amino acids in the amino acid sequence set forth in SEQ ID NO:
7,
the VL comprises a VL complementarity-determining region (CDR) 1 (VLCDR1), a VLCDR2, and a VLCDR3,
the VLCDR1 comprises an amino acid sequence set forth in SEQ ID NO:
8, or an amino acid sequence having substitution, addition, or deletion of one or two amino acids in the amino acid sequence set forth in SEQ ID NO:
8,
the VLCDR2 comprises an amino acid sequence set forth in SEQ ID NO:
9, or an amino acid sequence having substitution, addition, or deletion of one or two amino acids in the amino acid sequence set forth in SEQ ID NO:
9, and
the VLCDR3 comprises an amino acid sequence set forth in SEQ ID NO:
10, or an amino acid sequence having substitution, addition, or deletion of one or two amino acids in the amino acid sequence set forth in SEQ ID NO:
10.

17 more elements

An antibody specifically binding to human growth hormone or an antigen-binding fragment thereof, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein

the VH comprises an amino acid sequence set forth in SEQ ID NO:
5 as a VH complementarity-determining region (CDR) 1 (VHCDR1), an amino acid sequence set forth in SEQ ID NO:
6 as a VHCDR2, and an amino acid sequence set forth in SEQ ID NO:
7 as a VHCDR3, and
the VL comprises an amino acid sequence set forth in SEQ ID NO:
8 as a VL complementarity-determining region (CDR) 1 (VLCDR1), an amino acid sequence set forth in SEQ ID NO:
9 as a VLCDR2, and an amino acid sequence set forth in SEQ ID NO:
10 as a VLCDR3.

5 more elements

Dependencies are inferred from the claim text.